CAI (Caris Life Sciences) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI Caris Life Sciences Inc CAI
12 GF Score
Price $25.07
! 4 Warning Signs
View Full Analysis

What is Caris Life Sciences 3-Year EBITDA Growth Rate?

Caris Life Sciences CAI -0.95% 12 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CAI with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Caris Life Sciences ranks worse than 88731.06% on this metric.

Caris Life Sciences's EBITDA per Share for the three months ended in Jun. 2026 was $0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Caris Life Sciences  (NAS:CAI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Caris Life Sciences 3-Year EBITDA Growth Rate Related Terms

CAI vs RYTM, SRRK, CGON: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Caris Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caris Life Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caris Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Caris Life Sciences's 3-Year EBITDA Growth Rate falls into.


CAI
12GF Score
Caris Life Sciences Inc CAI
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caris Life Sciences 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Caris Life Sciences (CAI) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Caris Life Sciences and its competitors. According to the industry distribution chart, Caris Life Sciences ranks #999999 out of 1127 companies in the Biotechnology industry.
Is Caris Life Sciences' 3-Year EBITDA Growth Rate too high?
Caris Life Sciences' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Caris Life Sciences ranks #999999 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' 3-Year EBITDA Growth Rate compare to RYTM and SRRK?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #999999 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Caris Life Sciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Caris Life Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Caris Life Sciences' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caris Life Sciences Business Description

Other Exchanges CAI:Mexico49J:Germany
Address 750 W. John Carpenter Freeway, Suite 800, Irving, TX, USA, 75039
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score

Get the complete analysis for CAI

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price